Rokit Healthcare secures 30 billion won ($22M) for UAE 3D bioprinting joint venture

Rokit Healthcare has secured 30 billion won (approximately $22 million) to establish a joint venture with a UAE-based investment firm, bringing 3D bioprinted tissue technology to the Gulf market.

The investment, disclosed on 14 April 2026 through Korean financial media, will fund a new entity focused on Rokit's regenerative medicine technology in the UAE and the wider Middle East. Rokit is best known for its Dr. INVIVO bioprinter, a clinical-grade device that prints living tissue for skin grafts, bone regeneration, and cartilage repair.

What the JV means for UAE operators

The deal arrives as UAE investors increase their bets on applied biotech. The UAE's healthcare sector has absorbed $4.5 billion in announced health tech and medtech investments since 2023, according to UAE Ministry of Economy trade disclosures, with Abu Dhabi and Dubai competing to attract advanced therapeutics companies.

For hospital operators and medical directors, 3D bioprinted tissue has direct clinical relevance. Rokit's platform targets diabetic wound care, a segment with heavy demand in the Gulf. The International Diabetes Federation estimates that 16.3% of the UAE's adult population lives with diabetes, one of the highest prevalence rates globally. Chronic wound management, including diabetic foot ulcers, consumes a disproportionate share of inpatient bed-days across the country's public and private hospitals.

Clinical deployment of bioprinted tissue products in the UAE would require multiple regulatory clearances:

• Federal product registration with the Ministry of Health and Prevention (MOHAP)
• Facility-level authorization from the Dubai Health Authority (DHA) or the Department of Health Abu Dhabi (DOH), depending on the JV's base of operations
• Full Class III clinical evaluation under the UAE's medical device regulatory framework, updated in 2024
• An estimated 18 to 24 months from submission to approval for bioprinted tissue products

South Korea's medtech push into the Gulf

Rokit's move follows a pattern among Korean medtech firms, which have accelerated Gulf expansion over the past two years. Abu Dhabi's ADQ and Mubadala have both allocated capital to biotech ventures. Dubai's D33 economic agenda lists advanced health sciences among its priority sectors through 2033.

The 30 billion won commitment places this deal among the mid-tier medtech JVs the region has attracted. The UAE's medtech imports totalled approximately AED 11 billion in 2025, with South Korea ranking among the top 10 source countries for diagnostic and therapeutic devices.

What to watch

The deal's operational impact depends on several unknowns: which emirate the JV will base in, whether Rokit plans local manufacturing or distribution only, and whether the company seeks MOHAP registration for its wound care applications first or pursues a broader product portfolio.

CIOs and procurement heads at major hospital groups should monitor the JV's regulatory filings. If Rokit secures MOHAP approval for wound care, it would become one of the first 3D bioprinting companies with a registered clinical product in the Gulf. That changes the procurement calculus for any facility running a wound care programme.

The identity of the UAE investment partner has not been disclosed in English-language reporting. Korean financial filings may provide additional detail in the coming weeks.